Cargando…

The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital

PURPOSE: MBL and OXA-48 genes in carbapenem-resistant Enterobacterales (CRE) have emerged as a major public health problem worldwide, including Thailand. Due to the lack of susceptibility data and dosing regimens of ceftazidime-avibactam (CZA) against CRE in Thailand, especially in colistin-resistan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasomsong, Worapong, Nulsopapon, Parnrada, Changpradub, Dhitiwat, Pongchaidecha, Manat, Pungcharoenkijkul, Supanun, Juntanawiwat, Piraporn, Simsiriporn, Waristha, Santimaleeworagun, Wichai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291577/ https://www.ncbi.nlm.nih.gov/pubmed/34295150 http://dx.doi.org/10.2147/DDDT.S321147

Ejemplares similares

The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates
por: Nulsopapon, Parnrada, et al.
Publicado: (2021)

Correction: Nulsopapon et al. The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates. Antibiotics 2021, 10, 736
por: Nulsopapon, Parnrada, et al.
Publicado: (2022)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant Acinetobacter baumannii: Improved Efficacy or Decreased Risk of Nephrotoxicity?
por: Saelim, Weerayuth, et al.
Publicado: (2021)

The Activities of Antimicrobials Against Stenotrophomonas maltophilia Isolates and Evaluation of Clinical Outcomes Among Treatment Regimens in Patients with Stenotrophomonas maltophilia Infections: A Retrospective Multicenter Cohort Study
por: Boonmee, Patchrapa, et al.
Publicado: (2023)

Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western Thailand
por: Nulsopapon, Parnrada, et al.
Publicado: (2022)

Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting
por: Pongchaidecha, Manat, et al.
Publicado: (2020)

Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2019)

First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience
por: Nasomsong, Worapong, et al.
Publicado: (2021)

Impact of Inappropriate Empirical Antibiotic on Outcomes in Community-acquired Third Generation Cephalosporin Resistant Enterobacterales Bacteremia
por: Nasomsong, Worapong, et al.
Publicado: (2022)

Antimicrobials as Single and Combination Therapy for Colistin-Resistant Pseudomonas aeruginosa at a University Hospital in Thailand
por: Pungcharoenkijkul, Supanun, et al.
Publicado: (2020)

Is Echocardiography Mandatory for All Streptococcus gallolyticus Subsp. pasteurianus Bacteremia?
por: Nasomsong, Worapong, et al.
Publicado: (2020)

Clinical Impact of Vancomycin Treatment in Ampicillin-Susceptible Enterococci Bloodstream Infections
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2022)

Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections
por: Santimaleeworagun, Wichai, et al.
Publicado: (2020)

Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2019)

Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections
por: Hemapanpairoa, Jatapat, et al.
Publicado: (2021)

Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2021)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae
por: Cui, Qiaozhen, et al.
Publicado: (2023)

Is Early Monitoring Better? Impact of Early Vancomycin Exposure on Treatment Outcomes and Nephrotoxicity in Patients with Methicillin-Resistant Staphylococcus aureus Infections
por: Chattaweelarp, Thanawat, et al.
Publicado: (2020)

2284. Treatment and Clinical Outcomes Among Infected Patients with Colistin-resistant Klebsiella pneumoniae Bacteremia.
por: Prawang, Abhisit, et al.
Publicado: (2019)

Ceftazidime-avibactam based combinations against carbapenemase producing Klebsiella pneumoniae harboring hypervirulence plasmids
por: Bulman, Zackery P., et al.
Publicado: (2022)

Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021)

Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022)

In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae
por: Zhang, Wenxia, et al.
Publicado: (2018)

Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China
por: Zhu, Yiwei, et al.
Publicado: (2021)

Epidemiology of resistance of carbapenemase‐producing Klebsiella pneumoniae to ceftazidime‐avibactam in a Chinese hospital
por: Chen, D., et al.
Publicado: (2021)

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae
por: List, Karoline Knudsen, et al.
Publicado: (2022)

Prosthetic Joint Infection from Carbapenemase-Resistant Klebsiella pneumoniae Successfully Treated with Ceftazidime-Avibactam
por: Schimmenti, A., et al.
Publicado: (2018)

Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiellapneumoniae infections
por: Wannigama, Dhammika Leshan, et al.
Publicado: (2023)

Ceftazidime/avibactam for specified infections
Publicado: (2020)

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation
por: Limcharoen, Sutee, et al.
Publicado: (2022)

Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline
por: Guedes, Mariana, et al.
Publicado: (2020)

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland
por: Nordmann, Patrice, et al.
Publicado: (2023)

1313. MIC Profiling of Ceftazidime-Avibactam (CAZ/AVI) Against Two Carbapenemase producing Klebsiella pneumoniae Isolates
por: Zidaru, Andrei, et al.
Publicado: (2020)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
por: Huang, Zeyu, et al.
Publicado: (2023)

Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae subsp. pneumoniae Isolates in a Tertiary Italian Hospital: Identification of a New Mutation of the Carbapenemase Type 3 (KPC-3) Gene Conferring Ceftazidime/Avibactam Resistance
por: Fontana, Carla, et al.
Publicado: (2021)

Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital
por: Poovieng, Jaturon, et al.
Publicado: (2022)

Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam
por: Hobson, Claire Amaris, et al.
Publicado: (2020)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

In vivo Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Klebsiella pneumoniae Isolate With KPC-33 Carbapenemase
por: Wang, Chunlei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bl8hn8jbm8qdsii3m0kfl9catk